TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA’s late stage pipeline Targeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025 Cross product and technology synergies build on TuHURA’s therapeutic focus on overcoming primary and acquired resistance to cancer immunotherapy Proposed Transaction expected to [...]
High-speed Rail Manufacturing Facility Coming to Horseheads
Monday, September 9th 2024, 7:01 PM EDT By Renata Stiehl By Linsey Madison Go to Article HORSEHEADS, NY (WENY) -- Senate Majority Leader Chuck Schumer (D-NY) visited Horseheads on Monday to announce the Southern Tier has been selected as the site of a manufacturing hub to build American high-speed rail [...]
Exploring the Surge of Private Equity in Over 33% of American Sports Teams
September 14, 2023 by Brendon Oliver Go to Article Private equity sports investment is on the rise. As leagues have eased ownership rules, dealmakers spy opportunities to gain outsized returns and cultural influence. It's no wonder why: US sports teams' valuations have grown faster than the S&P 500 in recent [...]
Kineta to Receive $5 Million Milestone Payment from Merck
Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS) SEATTLE, June 29, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the achievement of a development milestone which [...]
A heart was flown from Alaska to Boston, breaking a transplant record. Here’s how it was done.
Adrianna Rodriguez USA TODAY Dr. Joseph Rubelowsky felt as if he had just robbed a bank. Still in his scrubs, he boarded the Falcon 900 jet, sat down and glanced over at the white cooling contraption that held the day’s loot. Strapped to the aircraft floor, it looked like a [...]
Kineta Set to Join Russell Microcap® Index
SEATTLE, May 24, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company is set to join the Russell Microcap® Index at the conclusion of the 2023 Russell indexes annual reconstitution, [...]
Surgeon General Issues New Advisory About Effects Social Media Use Has on Youth Mental Health
Surgeon General Dr. Vivek Murthy Urges Action to Ensure Social Media Environments are Healthy and Safe, as Previously-Advised National Youth Mental Health Crisis Continues Today, United States Surgeon General Dr. Vivek Murthy released a new Surgeon General’s Advisory on Social Media and Youth Mental Health - PDF. While social media [...]
Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, April 24, 2023 — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has closed its previously announced registered direct offering for the purchase and sale of 1,425,179 [...]